Repligen Corporation [RGEN] Q2 2024 Earnings Conference Call July 30, 2024 8:30 AM ET
Company Participants
Tony Hunt - CEO
Jason Garland - CFO
Olivier Loeillot - President & CCO
Sondra Newman - IR
Conference Call Participants
Rachel Vatnsdal - J.P. Morgan
Dan Arias - Stifel
Jacob Johnson - Stephens Inc.
Puneet Souda - Leerink Partners
Justin Bowers - Deutsche Bank
Matt Larew - William Blair
Conor McNamara - RBC Capital Markets
Dan Leonard - UBS
Paul Knight - KeyBanc
Matt Hewitt - Craig-Hallum Capital Group
Matt Stanton - Jefferies
Tom DeBourcy - Nephron Research
Subbu Nambi - Guggenheim Securities
Operator
Good day, ladies and gentlemen, and welcome to Repligen Corporation's Second Quarter of 2024 Earnings Conference Call. [Operator Instructions]. I would now like to turn the call over to your host, Sondra Newman, Head of Investor Relations for Repligen. Please go ahead.
Sondra Newman
Thank you, and welcome to our second quarter of 2024 report. On this call, we will cover business highlights and financial performance for the three- and six-month period ending June 30, 2024, and we will provide financial guidance for the year 2024. Joining us on the call today are Repligen's current Chief Executive Officer, Tony Hunt; our Chief Commercial Officer, Olivier Loeillot, and our Chief Financial Officer, Jason Garland.
As a reminder, the forward-looking statements that we make during this call, including those regarding our business goals and expectations for the financial performance of the company, are subject to risks and uncertainties that may cause actual events or results to differ. Additional information concerning risks related to our business is included in our quarterly reports on Form 10-Q, our annual report on Form 10-K, and other current reports on 8-K, including the report that we're filing today and other filings that we make with the Securities and Exchange Commission. Today's comments reflect management's current views, which could change as a result of new information, future events or otherwise. The company does not obligate or commit itself to update forward-looking statements, except as required by law. During this call, we are providing non-GAAP financial results and guidance, unless otherwise noted. Reconciliations of GAAP to non-GAAP financial measures are included in the press release that we issued this morning, which is posted to Repligen's website and on sec.gov. Adjusted non-GAAP figures in today's report, include the following, base revenue and organic revenue, non-COVID and non-protein revenue, cost of sales, gross profit and gross margin, operating expenses, including R&D and SG&A, income from operations and operating margins, other income, pretax income, tax provision, effective tax rate, net income, diluted earnings per share, as well as EBITDA, adjusted EBITDA, and adjusted EBITDA margins. These adjusted financial measures should not be viewed as an alternative to GAAP measures, but are intended to best reflect the performance of our ongoing operations.